
How RSV manipulates the immune response in respiratory cells
TWINCORE researchers investigate gene activity in host cells

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium will take place on 3 - 4 September.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal

The 23rd doctoral thesis to receive an award at TWINCORE
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Dinkelborg K, Niehaus C, Bremer B, Wundes C, Tiede A, Petruch N, Deterding K, Kraft A, Hartleben B, Cornberg M, Wedemeyer H, Behrendt P, Maasoumy B
Berg K, Haid S, Vafadarnejad E, Carpentier A, Geffers R, Wiegmann B, Saliba A, Erhard F, Pietschmann T
Behrens M, Terroba-Navajas P, Willemse E, Schädelin S, Comabella M, Münz C, Lauc G, Bartsch Y, Kuhle J, Lünemann J
The project investigates the immune response of the central nervous system in viral infections, in particular the role of type I IFN, microglia and monocytes in the development of encephalitis and their influence on seizures and hippocampal damage.
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
Human, potentially neutralizing antibodies against HEV have advanced the development of new detection methods for the virus in patient samples. Serological and functional analyses are used to determine markers for the course and treatment of chronic infections.

